Značaj učestalosti populacije CD14+B7-H4+ ćelija koje odgovaraju mijeloidnim supresivnim ćelijama (MDSC) u krvi i tumorskoj mikrocirkulaciji bolesnika sa karcinomom pluća
Sažetak
Uvod/Cilj. Mijeloidne supresorske ćelije [myeolid derived suppressor cells (MDSCs)] negativno regulišu imunski odgovor nizom inhibitornih mehanizama koji konačno omogućavaju rast tumora. Ispoljavanje B7-H4 je značajno povezano sa lošim ishodom, kao i promocijom proliferacije, invazije i migracije ćelija tumora kod bolesnika sa različitim tipovima
karcinoma. Podaci koji prikazuju ispoljavanje B7-H4 u tumorima pluća, na tumorskim ili imunskim ćelijama, su i dalje retki. Cilj rada bio je utvrditi i korelirati zastupljenost CD14+B7-H4+ ćelija sličnih MDSCs (CD14+B7-H4+ MDSCs) u krvi i mikrocirkulaciji tumora pluća sa kliničkim stadijumom, histološkim tipom tumora, tumor nodus metastaza (TNM) stadijumom, nodalnim statusom i raširenošću bolesti. Metode. U studiju je bilo uključeno 44 bolesnika sa karcinomom pluća (III i IV klinički stadijum) i 30 zdravih osoba. Zastupljenost (%) CD14+B7-H4+ MDSCs je bila utvrđena protočnom citometrijom u krvi i mikrocirkulaciji tumora svakog bolesnika. Rezultati. Zastupljenost CD14+B7-H4+ MDSCs bila je značajno veća u uzorcima bolesnika u odnosu na kontrole. CD14+B7-H4+ MDSCs u uzorku tumora su bile značajno brojnije u odnosu na uzorak krvi istog bolesnika. Bolesnici III kliničkog stadijuma imali su povećane vrednosti CD14+B7-H4+ MDSCs u odnosu na one u IV stadijumu, u obe vrste uzoraka. Prema histološkom tipu, bolesnici sa sitnoćelijskim karcinomom pluća imali su najveće vrednosti CD14+B7-H4+ MDSCs, značajno povećane u odnosu na bolesnike sa skvamoznim ili giganto-ćelijskim tipom tumora. Veličina tumora bila je direktno udružena sa brojem CD14+B7-H4+ MDSCs, u obe vrste uzoraka. Zahvaćenost limfnih žlezda bila je udružena sa postepenim povećanjem vrednosti CD14+B7-H4+ MDSCs, sa najvećim vrednostima u N3 grupi, u obe vrste uzoraka. Na kraju, detektovali smo veće vrednosti CD14+B7-H4+MDSCs u uzorcima bolesnika bez metastaza. Zaključak. Vrednosti CD14+B7-H4+ MDSCs kod bolesnika sa karcinomom pluća značajno su povezane sa histološkim tipom tumora, zahvatanjem limfnih čvorova, stepenom raširenosti bolesti i veličinom tumora. S obzirom na visoke vrednosti u mikrookruženju tumora pluća zajedno sa njihovim imunosupresivnim kapacitetima, CD14+B7-H4+ MDSCs mogu predstavljati važan promovišući faktor u patofiziologiji karcinoma pluća.
Reference
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, еt al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5): E359‒86.
Ni L, Dong C. New B7 family checkpoints in human cancers. Mol Cancer Ther 2017; 16(7): 1203–11.
Sica GL, Choi IH, Zhu G, Tamada K, Wang SD, Tamura H, et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 2003; 18(6): 849‒61.
Prasad DV, Richards S, Mai XM, Dong C. B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 2003; 18(6): 863‒73.
Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006; 203(4): 871‒81.
Kryczek I, Wei S, Zhu G, Myers L, Mottram P, Cheng P, et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 2007; 67(18): 8900‒5.
Yao Y, Ye H, Qi Z, Mo L, Yue Q, Baral A, et al. B7-H4(B7x)-mediated cross-talk between glioma-initiating cells and macrophages via the IL6/JAK/STAT3 pathway lead to poor prognosis in glioma patients. Clin Cancer Res 2016; 22(11): 2778‒90.
Li J, Lee Y, Li Y, Jiang Y, Lu H, Zang W, et al. Co-inhibitory molecule B7 superfamily member 1 expressed by tumor-infiltrating myeloid cells induces dysfunction of anti-tumor CD8+ T cells. Immunity 2018; 48(4): 773‒86. e5.
Ortiz ML, Lu L, Ramachandran I, Gabrilovich I. Myeloid-derived suppressor cells in the development of lung cancer. Cancer Immunol Res 2014; 2(1): 50‒8.
Weber R, Fleming V, Hu X, Nagibin V, Groth C, Altevogt P, et al. Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors. Front Immunol 2018; 9: 1310.
Yamauchi Y, Safi S, Blattner C, Rathinasamy A, Umansky L, Juenger S, et al. Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non–Small Cell Lung Cancer. Am J Respir Crit Care Med 2018; 198(6): 777‒87.
Zhang G, Huang H, Zhu Y, Yu G, Gao X, Xu Y, et al. A novel subset of B7-H3+CD14+HLA-DR-/low myeloid-derived suppressor cells are associated with progression of human NSCLC. Oncoimmunology 2015; 4(2): e977164.
Stanojevic I, Miller K, Kandolf-Sekulovic L, Mijuskovic Z, Zolotarevski Z, Jovic M, et al. A subpopulation that may correspond to granulocytic myeloid-derived suppressor cells reflects the clinical stage and progression of cutaneous melanoma. Int Immunol 2016; 28(2): 87‒97.
Simon I, Katsaros D, Rigault de la Longrais I, Massobrio M, Scorilas A, Kim NW et al. B7-H4 is over-expressed in early - stage ovarian cancer and is independent of CA-125 expression. Gynecol Oncol 2007; 106(2): 334‒41.
Qian Y, Shen L, Cheng L, Wu Z, Yao H. B7-H4 expression in various tumors determined using a novel developed monoclonal antibody. Clin Exp Med 2011; 11(3): 163‒70.
Choi IH, Zhu G, Sica GL, Strome SE, Cheville JC, Lau JS, et al. Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J Immunol 2003; 171(9): 4650‒4.
Dangaj D, Lanitis E, Zhao A, Joshi S, Cheng Y, Sandaltzopoulos R, et al. Novel recombinant human B7-H4 antibodies overcome tumoral immune escape to potentiate T cell anti-tumor responses. Cancer Res 2013; 73(15): 4820‒9.
Kryczek I, Wei S, Zou L, Zhu G, Mottram P, Xu H, et al. Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol 2006; 177(1): 40–4.
Matsunaga T, Saito H, Ikeguchi M. Increased B7-H1 and B7-H4 Expressions on Circulating Monocytes and Tumor-Associated Macrophages are Involved in Immune Evasion in Patients with Gastric Cancer. Yonago Acta Med 2011; 54(1): 1‒10.
Tan Z, Shen W. Prognostic role of B7-H4 in patients with non-small cell lung cancer: A meta-analysis. Oncotarget 2017; 8(16): 27137‒44.
Chen Y, Pan G, Tian D, Zhang Y, Li T. Functional analysis of CD14+HLADR/low myeloid-derived suppressor cells in patients with lung squamous cell carcinoma. Oncol Lett 2017; 14(1): 349‒54.
Schneider T, Hoffmann H, Dienemann H, Schnabel PA, Enk AH, Ring S, et al. Non-small cell lung cancer induces an immunosuppressive phenotype of dendritic cells in tumor microenvironment by upregulating B7-H3. J Thorac Oncol 2011; 6(7): 1162‒8.
Huang A, Zhang B, Wang B, Zhang F, Fan KX, Guo Y. Increased CD14+HLA-DR-/low myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. Cancer Immunol Immunother 2013; 62(9): 1439‒51.
Hamilton G, Rath B, Klameth L, Hochmair MJ. Small cell lung cancer: Recruitment of macrophages by circulating tumor cells. Oncoimmunology 2015; 5(3): e1093277.
Feng PH, Yu CT, Chen KY, Luo CS, Wu SM, Liu CY, et al. S100A9+ MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: the role of RELB. Oncotarget 2018; 9(7): 7631‒43.
Karlicic V, Vukovic J, Stanojevic I, Sotirovic J, Peric A, Jovic M, et al. Association of locally produced IL10 and TGFb1 with tumor size, histological type and presence of metastases in patients with lung carcinoma. J BUON 2016; 21(5): 1210‒8.
Pogoda K, Pyszniak M, Rybojad P, Tabarkiewicz J. Monocytic myeloid-derived suppressor cells as a potent suppressor of tumor immunity in non-small cell lung cancer. Oncol Lett 2016; 12(6): 4785–94.
Heuvers ME, Muskens F, Bezemer K, Lambers M, Dingemans AM, Groen HJ, et al. Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patients. Lung Cancer 2013; 81(3): 468‒74.
Tian T, Gu X, Zhang B, Liu Y, Yuan C, Shao L, et al. Increased circulating CD14(+) HLA-DR-/low myeloid-derived suppressor cells are associated with poor prognosis in patients with small-cell lung cancer. Cancer Biomark 2015; 15(4): 425‒32.